Mar 17, 2022

Protein subunit COVID vaccine, which can be manufactured using engineered yeast, shows promise in preclinical studies

Posted by in category: biotech/medical

While many people in wealthier countries have been vaccinated against COVID-19, there is still a need for vaccination in much of the world. A new vaccine developed at MIT and Beth Israel Deaconess Medical Center may aid in those efforts, offering an inexpensive, easy-to-store, and effective alternative to RNA vaccines.

In a new paper, the researchers report that the vaccine, which comprises fragments of the SARS-CoV-2 spike arrayed on a virus-like particle, elicited a strong immune response and protected animals against viral challenge.

The vaccine was designed so that it can be produced by yeast, using fermentation facilities that already exist around the world. The Serum Institute of India, the world’s largest manufacturer of vaccines, is now producing large quantities of the vaccine and is running a clinical trial in Africa.

Leave a reply